These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3318450)

  • 61. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
    Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Kim JA; Lee Y; Shin EK
    Diabetes Care; 2006 Feb; 29(2):195-201. PubMed ID: 16443859
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
    Levin A; Duncan L; Djurdjev O; Shapiro RJ; Frohlich J; Belanger A; Dumas R; Ross S
    Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
    Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
    Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
    Barnard SD; Molello JA; Caldwell WJ; Lebeau JE
    Nouv Presse Med; 1980 Oct; 9(40):3005-7. PubMed ID: 7443440
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clofibrate, serum enzymes, and muscle pain.
    Smith AF; Macfie WG; Oliver MF
    Br Med J; 1970 Apr; 2(5701):86-8. PubMed ID: 5420239
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus.
    Genest J; Frohlich J; Steiner G
    Am J Cardiol; 2004 Apr; 93(7):848-53. PubMed ID: 15050487
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Biomolecular chemistry of isopropyl fibrates.
    Balendiran GK; Rath N; Kotheimer A; Miller C; Zeller M; Rath NP
    J Pharm Sci; 2012 Apr; 101(4):1555-69. PubMed ID: 22246648
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Amelioration of vincristine neurotoxicity by glutamic acid.
    Jackson DV; Wells HB; Atkins JN; Zekan PJ; White DR; Richards F; Cruz JM; Muss HB
    Am J Med; 1988 Jun; 84(6):1016-22. PubMed ID: 2897788
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fenofibrate therapy to lower serum triglyceride concentrations in persons with spinal cord injury: A preliminary analysis of its safety profile.
    La Fountaine MF; Cirnigliaro CM; Hobson JC; Lombard AT; Specht AF; Dyson-Hudson TA; Bauman WA
    J Spinal Cord Med; 2020 Sep; 43(5):704-709. PubMed ID: 30870136
    [No Abstract]   [Full Text] [Related]  

  • 75. [Severe mixed hepatitis caused by fenofibrate? A review of the literature apropos of a case].
    Rigal J; Furet Y; Autret E; Breteau M
    Rev Med Interne; 1989; 10(1):65-7. PubMed ID: 2655052
    [No Abstract]   [Full Text] [Related]  

  • 76. [Fenofibrate induced polymyositis].
    Sauvaget F; Piette JC; Herson S; De Gennes C; Duyckaerts C; Godeau P
    Rev Med Interne; 1991; 12(1):52-4. PubMed ID: 2041914
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Side effect and safety data for fenbufen.
    Crossley RJ
    Am J Med; 1983 Oct; 75(4B):84-90. PubMed ID: 6227235
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacology of fenofibrate.
    Chapman MJ
    Am J Med; 1987 Nov; 83(5B):21-5. PubMed ID: 3318449
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Propylthiouracil-induced hypothyroid hyperlipidemic chick: a model for clofibrate-induced toxicity.
    Raheja KL; Linscheer WG; Cho C
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1986; 85(2):397-400. PubMed ID: 2879699
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.
    Bakker-Arkema RG; Best J; Fayyad R; Heinonen TM; Marais AD; Nawrocki JW; Black DM
    Atherosclerosis; 1997 May; 131(1):17-23. PubMed ID: 9180240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.